About OnyvaxSciencePress ReleasesClinical TrialsCareersContact
Onyvax - oncology vaccines 

Current Press Releases

Archived Press Releases

Press Releases image

Archived Press Releases

March 29, 2004

Onyvax and University of Michigan Develop PSA Expressing Cell Lines for Prostate Cancer Vaccine Research

London, UK – 29 March, 2004: Onyvax Limited, the biotechnology company developing novel cancer therapies, and the University of Michigan Comprehensive Cancer Center announced the development of two novel metastatic prostate cancer cell lines for the development of Cell Vaccines at the 95th annual meeting of the American Association for Cancer Research (AACR), taking place in Orange County, Orlando from 27-31 March 2004.

The cell lines are particularly valuable because they are derived from metastatic deposits of prostate cancer and express prostate specific antigen (PSA). Very few prostate cell lines have been developed, the majority of which are derived from primary tissue and do not express PSA. These new cell lines therefore represent an invaluable resource for understanding basic prostate cancer biology and may also form the basis of second generation, improved performance Cell Vaccines to treat the disease.

Dr. Anthony Walker, CEO of Onyvax Ltd, said: "These cell lines and clones thereof are ideal candidates for future allogenic prostate cancer vaccines, particularly because of their PSA and other antigen expression, growth kinetics and scalability. This work would not have been possible without the world class scientific expertise and resources of our collaborators at the University of Michigan”

Professor Ken Pienta, Professor of Internal Medicine and Urology at University of Michigan, said “These cell lines will be useful additions to the existing models of prostate cancer and may enable more advanced studies into the mechanisms of prostate cancer progression and metastasis. Furthermore, they may have considerable therapeutic potential as components of a vaccine to treat prostate cancer.”

Onyvax is developing a number of cancer vaccines including Onyvax-P, a Cell Vaccine for the treatment of prostate cancer. Interim data from a Phase II clinical trial has shown that treatment with Onyvax-P slows down the rate of PSA release in men with hormone resistant prostate cancer and may also slow down the rate of disease progression. Onyvax expects to release final data from this trial later this year and is preparing to initiate phase III pivotal clinical trials within the next year.

For further information, please contact:

Dr Anthony Walker / Rob Johnson
+44 (0)20 8682 9119

Financial Dynamics
Francetta Carr / Lucy Briggs
+44 (0)20 7831 3113

Back to Current Releases Back to Current Releases

© 1998-2009 Onyvax Ltd. All Rights Reserved